MiSeq 1100 Plus System

The National Institutes of Health (NIH) Office of Logistics and Acquisition Operations, on behalf of the National Cancer Institute (NCI), intends to award a sole-source firm-fixed-price purchase order to Illumina, Inc. for an Illumina NextSeq 2000 desktop sequencing system and associated service contract under FAR Part 6.302-1 (Only One Responsible Source), with award anticipated approximately ten days after the Notice of Intent posted August 14, 2026.

The NCI requires the NextSeq 2000 to progress from tumor sample acquisition to finalized genetic analysis within 7–10 days, supporting personalized cancer treatment approaches. Continued use of an Illumina platform is necessary to maintain data comparability with the laboratory's extensive existing sequencing database and ensure compatibility with proprietary analytical pipelines—RNA-seq, exome-seq, whole-genome sequencing, single-cell whole-transcriptome analysis, and T-cell receptor sequencing—designed around Illumina reagents and systems. Transition to different sequencing technology would require substantial modification or complete redevelopment of these established pipelines. The Illumina service contract is critical to ensure proper system maintenance, repairs, and replacements, as manufacturer warranties require servicing by Illumina-authorized personnel.

Though this is a non-competitive procurement, interested small business concerns—including 8(a) participants, Service-Disabled Veteran-Owned Small Businesses, HUBZone small businesses, Small Disadvantaged Businesses, Veteran-Owned Small Businesses, and Women-Owned Small Businesses—may submit written capability statements demonstrating their ability to satisfy all technical, compatibility, maintenance, warranty, and programmatic requirements. Capability statements must be submitted by email to danielt@mail.nih.gov no later than 9:00 a.m. EST on August 24, 2026. Award will proceed unless capability statements demonstrate another organization can meet requirements.